Alkermes, through the merger with Elan Drug Technologies,to form Alkermes plc,has been developing and manufacturing commercial scale solid oral dosage products for over 40 years.This case study demonstrates the successful transfer of alow solubility compound into one of our manufacturing sites and achieving as a result, an OTIF (On-Time-In-Full) consistently over 95%.
- High Potency Manufacturing - Key selection criteria when evaluating an outsourcing partner
- Joint Risk Assessment During Technical Transfer – A Framework for Donor and Recipient Companies
- Alkermes’ successful approach to commercial scale final dosage manufacture of drug product containing highly potent API
- Pharmaceutical Outsourcing - key success factors